Pines Wealth Management LLC Has $326,000 Holdings in Becton, Dickinson and Company (NYSE:BDX)

Pines Wealth Management LLC boosted its position in Becton, Dickinson and Company (NYSE:BDX) by 20.9% during the first quarter, HoldingsChannel.com reports. The institutional investor owned 1,425 shares of the medical instruments supplier’s stock after acquiring an additional 246 shares during the quarter. Pines Wealth Management LLC’s holdings in Becton, Dickinson and Company were worth $326,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Bank of Jackson Hole Trust acquired a new position in Becton, Dickinson and Company in the 4th quarter valued at $25,000. REAP Financial Group LLC grew its stake in Becton, Dickinson and Company by 75.3% in the 4th quarter. REAP Financial Group LLC now owns 128 shares of the medical instruments supplier’s stock valued at $29,000 after buying an additional 55 shares during the last quarter. Sierra Ocean LLC acquired a new position in Becton, Dickinson and Company in the 4th quarter valued at $29,000. Picton Mahoney Asset Management grew its stake in Becton, Dickinson and Company by 61.4% in the 4th quarter. Picton Mahoney Asset Management now owns 142 shares of the medical instruments supplier’s stock valued at $32,000 after buying an additional 54 shares during the last quarter. Finally, Nexus Investment Management ULC bought a new stake in Becton, Dickinson and Company in the 1st quarter valued at $34,000. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Becton, Dickinson and Company Trading Up 1.4%

Shares of BDX stock opened at $173.47 on Friday. Becton, Dickinson and Company has a 12-month low of $163.33 and a 12-month high of $251.99. The company has a market capitalization of $49.72 billion, a P/E ratio of 28.82, a P/E/G ratio of 1.63 and a beta of 0.25. The firm has a 50-day moving average price of $186.95 and a 200 day moving average price of $214.78. The company has a quick ratio of 0.63, a current ratio of 1.13 and a debt-to-equity ratio of 0.69.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings results on Thursday, May 1st. The medical instruments supplier reported $3.35 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.28 by $0.07. Becton, Dickinson and Company had a net margin of 8.47% and a return on equity of 15.74%. The firm had revenue of $5.27 billion during the quarter, compared to the consensus estimate of $5.35 billion. During the same period last year, the firm posted $3.17 EPS. The firm’s quarterly revenue was up 4.5% on a year-over-year basis. Research analysts forecast that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, June 30th. Investors of record on Monday, June 9th will be issued a dividend of $1.04 per share. This represents a $4.16 annualized dividend and a yield of 2.40%. The ex-dividend date of this dividend is Monday, June 9th. Becton, Dickinson and Company’s dividend payout ratio is currently 79.39%.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the stock. Wells Fargo & Company downgraded shares of Becton, Dickinson and Company from an “overweight” rating to an “equal weight” rating in a report on Thursday, May 1st. Raymond James downgraded shares of Becton, Dickinson and Company from an “outperform” rating to a “market perform” rating in a report on Friday, May 2nd. Wall Street Zen downgraded shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a report on Friday, May 2nd. Morgan Stanley reduced their price target on shares of Becton, Dickinson and Company from $280.00 to $196.00 and set an “overweight” rating for the company in a report on Tuesday, May 6th. Finally, Citigroup downgraded shares of Becton, Dickinson and Company from a “strong-buy” rating to a “hold” rating and reduced their price target for the company from $217.00 to $185.00 in a report on Thursday, May 22nd. Eight equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $219.22.

Insider Activity at Becton, Dickinson and Company

In related news, EVP Richard Byrd sold 1,940 shares of Becton, Dickinson and Company stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $224.91, for a total transaction of $436,325.40. Following the completion of the transaction, the executive vice president now directly owns 7,411 shares of the company’s stock, valued at $1,666,808.01. This trade represents a 20.75% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Michael David Garrison sold 479 shares of the firm’s stock in a transaction dated Wednesday, April 9th. The shares were sold at an average price of $197.28, for a total transaction of $94,497.12. Following the completion of the sale, the executive vice president now owns 4,887 shares of the company’s stock, valued at $964,107.36. The trade was a 8.93% decrease in their position. The disclosure for this sale can be found here. Insiders sold 4,044 shares of company stock valued at $836,000 in the last ninety days. Insiders own 0.36% of the company’s stock.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.